[Stereotactic irradiation of liver metastases].
OBJECTIVE
A number of minimal-invasive methods have been developed for the treatment of non-resectable liver metastases. A focused high dose can be delivered to a liver tumor with sparing of surrounding normal liver tissue using non-invasive stereotactic techniques.


METHODS
Sixty-six metastases were treated stereotactically in 43 patients during a phase 2 trial.


RESULTS
There were no major side effects observed. The actuarial local control was 82% after 18 months. The median actuarial survival was 24 months. However, there was a significantly improved survival in patients without additional extrahepatic tumor manifestation at the time of treatment compared to those, who were treated in palliative intention (87% vs. 24% after 18 months, p = 0.001 (log-rank).


CONCLUSIONS
Stereotactic single dose irradiation is a non-invasive and safe treatment option for patients with inoperable liver metastases. Phase III studies will further evaluate this new approach.
Herfarth
K K
KK
Klinische Kooperationseinheit Strahlentherapeutische Onkologie, Deutsches Krebsforschungszentrum, Abt. E0500, Im Neuenheimer Feld 280, 69120 Heidelberg. klaus@herfarth.de
Debus
J
J
Lohr
F
F
Bahner
M L
ML
Wannenmacher
M
M
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000532:radiotherapy; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000532:radiotherapy; D005260:Female; D006801:Humans; D021621:Imaging, Three-Dimensional; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011880:Radiotherapy Planning, Computer-Assisted; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
Stereotaktische Bestrahlung von Lebermetastasen.